secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2024-12-19T23:59:59+00:00
Accession:  0001683168-24-008833
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Phio Pharmaceuticals announces SMC recommendation to escalate to third dose cohort in PH-762 Phase 1b trial
--------------------------------------------------------------------------------

- Safety Monitoring Committee reviewed safety data from second dose cohort and recommended escalation to next dose concentration.
- First two patients in second cohort showed complete response (100% tumor clearance) and partial response (90% clearance) at Day 36.
- No dose-limiting toxicities or serious adverse events reported in participants receiving intratumoral PH-762.
- PH-762 is being studied for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma in Phase 1b trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824008833/0001683168-24-008833-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824008833/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-008833

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer